First Patient Dosed in Phase 2 Trial of Bryostatin-1 in Long-term Use

First Patient Dosed in Phase 2 Trial of Bryostatin-1 in Long-term Use
A first patient has been dosed in a Phase 2 trial investigating the safety and long-term efficacy of bryostatin-1 in treating moderate and moderately severe Alzheimer’s disease, the therapy’s developer, Neurotrope, announced. The trial (NCT04538066), which is recruiting patients at several sites across the U.S., will build on data from previous studies assessing bryostatin-1. Specifically, it is looking at the investigative therapy's long-term effectiveness on aiding cognition in people not using Namenda (memantine), an approved Alzheimer’s treatment marketed by Allergan. The study, which opened this year, aims to enroll about 100 patients with moderate and moderately severe Alzheimer’s, as measured by the mini-mental state examination (MMSE-2). Those enrolled will be randomly assigned to either bryostatin-1 or a placebo — both in the absence of Namenda — for two 11-week dosing cycles, given over six months. Its main goal will be to assess the long-term effects of bryostatin-1 on patients’ cognitive function, as measured by the Severe Impairment Battery (SIB), a test used to assess cognition in p
Subscribe or to access all post and page content.